BioMed Central

Q BioMed Inc Announces Acquisition of Cancer Pain Drug Metastron™ from GE Healthcare

Retrieved on: 
Wednesday, November 28, 2018
Strontium-89, BioMed Central, BIOMED, Metástasis, Publishing, Health

Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to announce that it has entered into agreement to acquire the metastatic skeletal cancer palliation drug, Metastron, from GE Healthcare.

Key Points: 
  • Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to announce that it has entered into agreement to acquire the metastatic skeletal cancer palliation drug, Metastron, from GE Healthcare.
  • The agreement gives Q BioMed ownership of the brand, trademarks and market authorizations in 22 countries.
  • Q BioMed CEO Denis Corin said of the deal, "This is a major deal for Q BioMed.
  • Strategically, it affirms our belief in this drug as an effective and underutilized non-opioid therapy for the treatment of debilitating pain associated with skeletal cancer metastases.

BioMed Realty Announces First Major Tenant At Gateway Of Pacific, The Latest Expansion Of Life Science, Technology And Healthcare Relationships In Its Bay Area Portfolio

Retrieved on: 
Wednesday, November 7, 2018
BioMed Central, AbbVie Inc., BIOMED, Publishing, Biotechnology, Health

This transaction is the culmination of tremendous leasing success for BioMed Realty in the Bay Area in 2018, bringing total leasing activity in 2018 to over 1.2 million square feet.

Key Points: 
  • This transaction is the culmination of tremendous leasing success for BioMed Realty in the Bay Area in 2018, bringing total leasing activity in 2018 to over 1.2 million square feet.
  • Gateway of Pacific is transforming the entrance to South San Francisco at the corner of Gateway Boulevard and Oyster Point Boulevard into the Bay Area's premier hub for life science innovation.
  • "We are thrilled to welcome a blue chip enterprise like AbbVie to the first phase of Gateway of Pacific," said Tim Schoen, President and CEO of BioMed Realty.
  • The recent expansion and addition of several research and healthcare companies, including the University Healthcare Alliance, an affiliate of Stanford Healthcare, successfully brought Pacific Research Center to 100 percent leased.

Q Biomed Inc. Announces Dr. Rajendra Apte Joins Advisory Board

Retrieved on: 
Monday, September 17, 2018
Indian films, Apte, BIOMED, BioMed Central, X: Past Is Present, Ophthalmology, Publishing, Cinema of India

NEW YORK, Sept. 17, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce that Rajendra Apte, MD, PhD has joined its Advisory Board contributing his extensive experience in the field of ophthalmology ( https://wuphysicians.wustl.edu/for-patients/featured-physicians/rajendra... ).

Key Points: 
  • NEW YORK, Sept. 17, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce that Rajendra Apte, MD, PhD has joined its Advisory Board contributing his extensive experience in the field of ophthalmology ( https://wuphysicians.wustl.edu/for-patients/featured-physicians/rajendra... ).
  • Dr. Apte is the Paul A. Cibis Distinguished Professor of Ophthalmologyand Visual Sciences at Washington University in St. Louis.
  • Dr. Apte is currently running a human study to investigate the correlation of GDF-15 levels with glaucoma disease severity and progression.
  • "We are honored to have Dr. Apte join our distinguished team of scientific advisors," said Denis Corin, CEO of Q BioMed.

Glenmark Pharmaceuticals and Harbour BioMed Sign Agreement for Greater China to Develop GBR 1302, a First-in-Class Bispecific Antibody for Treatment of HER2-Positive Cancers

Retrieved on: 
Monday, August 6, 2018
Immunology, Immune system, BioMed Central, Antibody, Biology, Health, Publishing

This collaboration is aligned with our strategy to leverage our clinical development expertise by in-licensing highly innovative clinical stage assets.

Key Points: 
  • This collaboration is aligned with our strategy to leverage our clinical development expertise by in-licensing highly innovative clinical stage assets.
  • GBR 1302 is complementary to the internal portfolio we are building through our industry leading transgenic mouse platforms for generating innovative antibody-based therapeutics."
  • Harbour BioMed will lead the clinical development and commercialization of GBR 1302, with the option to manufacture GBR 1302 for the Greater China market.
  • Harbour BioMed also licenses the platforms to companies and academic institutions through its Harbour Antibodies subsidiary.

Glenmark Pharmaceuticals and Harbour BioMed Sign Agreement for Greater China to Develop GBR 1302, a First-in-Class Bispecific Antibody for Treatment of HER2-Positive Cancers

Retrieved on: 
Monday, August 6, 2018
Immunology, Immune system, BioMed Central, Antibody, Biology, Health, Publishing

This collaboration is aligned with our strategy to leverage our clinical development expertise by in-licensing highly innovative clinical stage assets.

Key Points: 
  • This collaboration is aligned with our strategy to leverage our clinical development expertise by in-licensing highly innovative clinical stage assets.
  • GBR 1302 is complementary to the internal portfolio we are building through our industry leading transgenic mouse platforms for generating innovative antibody-based therapeutics."
  • Harbour BioMed will lead the clinical development and commercialization of GBR 1302, with the option to manufacture GBR 1302 for the Greater China market.
  • Harbour BioMed also licenses the platforms to companies and academic institutions through its Harbour Antibodies subsidiary.

LA BioMed helps drive LA County's ranking as national Top-10 BioPharma Cluster

Retrieved on: 
Thursday, June 7, 2018
BIOMED, BioMed Central, Biotechnology, Publishing

Genetic Engineering & Biotechnology News (GEN) has highlighted LA BioMed as the centerpiece of a growing biotech cluster in Los Angeles and Orange County.

Key Points: 
  • Genetic Engineering & Biotechnology News (GEN) has highlighted LA BioMed as the centerpiece of a growing biotech cluster in Los Angeles and Orange County.
  • "LA BioMed is home to groundbreaking biomedical research and the development of breakthrough therapies that save lives," said LA BioMed CEO David Meyer.
  • We are proud LA BioMed is an essential piece to one of the nation's most influential and fastest-growing biotech clusters."
  • LA BioMed is an incubator of innovation with a global reach and a 66-year reputation of improving and saving lives.

Q BioMed Inc. Provides Important Update on Mannin Research Tie2 Technology Platform Development

Retrieved on: 
Wednesday, June 6, 2018
Tyrosine kinase receptors, TEK tyrosine kinase, Angiopoietin receptor, BioMed Central, Publishing

Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, provides the following update on its exclusively licensed platform technology asset from Mannin Research Inc.

Key Points: 
  • Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, provides the following update on its exclusively licensed platform technology asset from Mannin Research Inc.
  • They recently filed patents with the United States Patent and Trademark Office disclosing novel compounds capable of activating Tie2 receptor-mediated signaling.
  • a biologic vs. a small molecule, from which to build a biologic-based therapeutic platform targeting Tie2 receptor for the treatment of glaucoma and other vascular diseases.
  • Q BioMed and Mannin representatives are also attending The BIO International Convention (BIO 2018) on June 4-7, 2018 in Boston, MA.

LA BioMed recruits Chronicle of Philanthropy Superstar as New Vice President for Development

Retrieved on: 
Tuesday, May 8, 2018
Biomedical Research Institute, BIOMED, BioMed Central, Publishing

LOS ANGELES, May 8, 2018 /PRNewswire/ --To elevate its fundraising progress, LA BioMed CEO David Meyer announced the addition of Ernie Iseminger as the new Vice President of Development at The Los Angeles Biomedical Research Institute (LA BioMed).

Key Points: 
  • LOS ANGELES, May 8, 2018 /PRNewswire/ --To elevate its fundraising progress, LA BioMed CEO David Meyer announced the addition of Ernie Iseminger as the new Vice President of Development at The Los Angeles Biomedical Research Institute (LA BioMed).
  • "Ernie will be integral to LA BioMed's next growth stage," said David Meyer, PhD, LA BioMed President and CEO.
  • Iseminger joins LA BioMed from the Claremont Graduate University, where, as a member of the Senior Cabinet he held the position of Vice President for Advancement, and oversaw Development, Marketing, Communications and Alumni Engagement.
  • LA BioMed is an incubator of innovation with a global reach and a 66-year reputation of changing and saving lives.